J B Chemicals and Pharmaceuticals Ltd
NSE:JBCHEPHARM

Watchlist Manager
J B Chemicals and Pharmaceuticals Ltd Logo
J B Chemicals and Pharmaceuticals Ltd
NSE:JBCHEPHARM
Watchlist
Price: 1 859.7 INR -1.7% Market Closed
Market Cap: 289.2B INR
Have any thoughts about
J B Chemicals and Pharmaceuticals Ltd?
Write Note

Net Margin
J B Chemicals and Pharmaceuticals Ltd

16.5%
Current
15%
Average
4.5%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
16.5%
=
Net Income
6.1B
/
Revenue
37.1B

Net Margin Across Competitors

Country IN
Market Cap 288.6B INR
Net Margin
16%
Country JP
Market Cap 776 550.9T JPY
Net Margin
-79%
Country US
Market Cap 756.3B USD
Net Margin
20%
Country UK
Market Cap 440.4B GBP
Net Margin
-4%
Country DK
Market Cap 2.7T DKK
Net Margin
35%
Country US
Market Cap 349.7B USD
Net Margin
17%
Country US
Market Cap 251.6B USD
Net Margin
19%
Country CH
Market Cap 199.5B CHF
Net Margin
20%
Country UK
Market Cap 161.6B GBP
Net Margin
13%
Country CH
Market Cap 171.3B CHF
Net Margin
35%
Country US
Market Cap 151.4B USD
Net Margin
7%
No Stocks Found

J B Chemicals and Pharmaceuticals Ltd
Glance View

Market Cap
288.6B INR
Industry
Pharmaceuticals

In the bustling marketplace of India's pharmaceutical industry, J B Chemicals and Pharmaceuticals Ltd. has carved its niche, a testament to its strategic vision and operational prowess. Founded in 1976 by Janak Mehta, the company has grown from its humble beginnings into a leading player in both the domestic and international arenas. Originally rooted in the ethos of quality and innovation, it established a firm foothold in the pharmaceutical sector through a diverse portfolio that includes formulations, active pharmaceutical ingredients (APIs), and contract manufacturing. As a vertically integrated company, J B Chemicals leverages its ability to control the manufacturing process from start to finish, ensuring strict quality measures and cost efficiencies, vital in tackling industry competition and regulatory challenges. The heart of J B Chemicals’ revenue model is its well-rounded product line that spans a range of therapeutic categories, including gastrointestinal, cardiovascular, and anticold segments. Blockbuster brands like Cilacar and Metrogyl have propelled the company to the top ranks within India, while its export division flourishes, contributing significantly to total earnings. With footprints in more than 30 countries, particularly in Russia and South Africa, the company taps into the growing demand for generic medicines worldwide. Moreover, by embracing innovation and investing in research and development, J B Chemicals continues to introduce new and improved medical solutions, positioning itself as a dynamic player in meeting global healthcare needs.

JBCHEPHARM Intrinsic Value
1 252.85 INR
Overvaluation 33%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
16.5%
=
Net Income
6.1B
/
Revenue
37.1B
What is the Net Margin of J B Chemicals and Pharmaceuticals Ltd?

Based on J B Chemicals and Pharmaceuticals Ltd's most recent financial statements, the company has Net Margin of 16.5%.